Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$24.17 - $36.01 $1.15 Million - $1.72 Million
-47,744 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$32.28 - $44.3 $804,934 - $1.1 Million
-24,936 Reduced 34.31%
47,744 $1.63 Million
Q4 2020

Feb 16, 2021

SELL
$31.45 - $40.54 $544,085 - $701,342
-17,300 Reduced 19.23%
72,680 $2.42 Million
Q3 2020

Nov 04, 2020

SELL
$26.0 - $34.5 $88,400 - $117,300
-3,400 Reduced 3.64%
89,980 $2.89 Million
Q2 2020

Jul 31, 2020

BUY
$14.11 - $29.42 $235,637 - $491,314
16,700 Added 21.78%
93,380 $2.57 Million
Q1 2020

May 08, 2020

SELL
$13.63 - $33.98 $265,785 - $662,609
-19,500 Reduced 20.27%
76,680 $1.23 Million
Q4 2019

Feb 11, 2020

BUY
$16.12 - $24.98 $283,712 - $439,648
17,600 Added 22.4%
96,180 $2.3 Million
Q3 2019

Nov 01, 2019

BUY
$15.49 - $25.78 $192,076 - $319,672
12,400 Added 18.74%
78,580 $1.39 Million
Q2 2019

Aug 13, 2019

BUY
$23.0 - $32.19 $962,228 - $1.35 Million
41,836 Added 171.85%
66,180 $1.69 Million
Q1 2019

May 15, 2019

SELL
$13.91 - $31.15 $6.13 Million - $13.7 Million
-441,000 Reduced 94.77%
24,344 $708,000
Q1 2019

May 13, 2019

BUY
$13.91 - $31.15 $6.05 Million - $13.5 Million
434,600 Added 1413.61%
465,344 $1.16 Million
Q4 2018

Feb 14, 2019

SELL
$11.6 - $18.7 $37,862 - $61,036
-3,264 Reduced 9.6%
30,744 $403,000
Q3 2018

Nov 14, 2018

BUY
$18.95 - $28.08 $96,645 - $143,208
5,100 Added 17.64%
34,008 $688,000
Q1 2018

May 03, 2018

BUY
$21.69 - $32.99 $627,014 - $953,674
28,908 New
28,908 $651,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.98B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Mackay Shields LLC Portfolio

Follow Mackay Shields LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mackay Shields LLC with notifications on news.